1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Pharmacologic exhaustion of suppressor cells with tasquinimod enhances bacterial clearance during tuberculosis
(
- Contribution to journal › Letter
- 2014
-
Mark
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
(
- Contribution to journal › Article
- 2013
-
Mark
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
(
- Contribution to journal › Article
- 2010
-
Mark
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
(
- Contribution to journal › Article
- 2009
-
Mark
Molecular insights into substrate specificity of prostate specific antigen through structural modeling
(
- Contribution to journal › Article
- 2006
-
Mark
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug
(
- Contribution to journal › Article
- 2001
-
Mark
Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing
(
- Contribution to journal › Article
- 1998
-
Mark
Enzymatic activation of a doxorubicin-peptide prodrug by prostate- specific antigen
(
- Contribution to journal › Article
- 1997
-
Mark
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
(
- Contribution to journal › Article